演者：浅野竜太郎准教授

人間総合科学研究科「医学セミナー」演題：タンパク質工学を駆使した次世代がん治療抗体の開発演者：浅野竜太郎准教授東京農工大学大学院工学研究院生命機能科学部門日付： 2016 年 12 月 2 日（金）時間：１８：30 ～ 19：３０場所：臨床講義室 C 本セミナーは主に英語で行われます。要旨： To
date, several types of recombinant antibody, e.g. fused with toxins,
multivalent, and multispecific, have been designed in efforts to develop next-generation
antibodies with higher function. Among recombinant antibodies, bispecific antibodies are
one of attractive formats that can bind to two different targets. This bispecificity can be
applied to cancer therapy by cross-linking between tumor cells and immune cells. We
have focused on small bispecific antibodies because they are easy to be modified through
genetic engineering, and found that a humanized small bispecific antibody, designated as
Ex3, that targets epidermal growth factor receptor (EGFR) on tumor cells and CD3 on
T-lymphocytes, had marked anticancer activity. Furthermore, the anticancer effect of Ex3
was enhanced by fusion with the human Fc region, multimerization, domain
rearrangement, and affinity maturation; a combination of these modifications showed at
least additive effects. Interestingly, merely rearranging the domain order of Ex3 induced
substantial cytotoxic enhancements, enhanced degradation resistance, and prolonged in
vivo half-life. More recently, we also constructed humanized anti-EGFR single-chain
variable fragment (scFv) multimers by modifying the linker length and the domain order,
and evaluated their ability to inhibit tumor growth. The anti-EGFR scFv multimers
inhibited cancer growth in a multimerization-dependent manner, whereas the anti-EGFR
scFv monomer showed no inhibitory effects. Here, I will present our efforts to develop
functional recombinant antibodies as next-generation cancer therapeutic reagents using
protein engineering. 連絡先：医学医療系細菌学森川一也 (3928, 7882)
<This seminar will be held in English.>
Date: Dec. 2 (Fri) 2016 18:30-19:30
Venue: Clinical Lecture Room C
Title: Development of next-generation cancer
therapeutic antibodies by using protein engineering
Speaker: Dr. Ryutaro Asano
Department of Biotechnology and Life Science,
Graduate School of Engineering,
Tokyo University of Agriculture and Technology
Kazuya Morikawa, Department of Infection Biology (Bacteriology)
[email protected] 029-853-7882

Download Report